Quek Richard, George Suzanne
Visiting Fellow, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
Biologics. 2010 Feb 4;4:19-31. doi: 10.2147/btt.s4396.
In the last decade a tremendous amount has been learned about the biology and treatment of gastrointestinal stromal tumor (GIST). Imatinib mesylate has revolutionized the treatment of metastatic GIST. In addition, the role of imatinib in localized GIST has gained much interest and may improve patient outcomes. Additionally, research efforts aimed at understanding the biology and the molecular heterogeneity of GIST both at initial presentation and at the time of resistance to imatinib, has helped guide rational approaches to treatment as well as future efforts aimed at treating imatinib-resistant GIST.
在过去十年中，我们对胃肠道间质瘤（GIST）的生物学特性及治疗方法有了大量的了解。甲磺酸伊马替尼彻底改变了转移性GIST的治疗方式。此外，伊马替尼在局限性GIST中的作用也备受关注，可能会改善患者的治疗效果。此外，旨在了解GIST在初次诊断时以及对伊马替尼耐药时的生物学特性和分子异质性的研究工作，有助于指导合理的治疗方法以及未来针对伊马替尼耐药性GIST的治疗努力。
